Let's Rebuild 340B as a Patient-Centric Model, ACCC Executive Director Recommends
April 29th 2017Christian G. Downs, JD, MHA, discusses his thoughts on how rebuilding the 340B program should be addressed, Medicare Payment Advisory Commission’s Part B cost control proposals, and the potential for progress in tackling rising drug costs.
Read More
How Cabozantinib is Being Used in Practice for Patients With RCC
April 28th 2017Daniel James George, MD, professor of Medicine, professor in Surgery, Duke University School of Medicine, discusses how cabozantinib (Cabometyx) is currently being used in practice for patients with renal cell carcinoma (RCC).
Watch
Genetic Testing Worth the Time, Effort, and Money, Burris Says
April 28th 2017The molecular profile of a patient with cancer who is about to be treated for their metastatic disease is the most critical piece of information you can have for that patient, according to Howard A. “Skip” Burris III, MD.
Read More
ACCC Health Policy Director Addresses ACA Repeal, MedPAC's Part B Recommendations
April 28th 2017Leah Ralph discusses the ACCC’s position on the ACA repeal bill, the Medicare Payment Advisory Commission’s (MedPAC) Part B cost control proposals, and the possibility for comprehensive reform on the 340B Drug Discount Program.
Read More
PBMs Extend Encroachment Into Physician Dispensing
April 27th 2017An April report from COA stated that PBMs have been calling patients and urging them to get their drugs from PBM-owned pharmacy networks, rather than through physician dispensaries. At this year’s Community Oncology Conference, presentations and discussions focused on this report.
Read More
How Oral Targeted Therapies and IV Immunotherapies Disrupted Community Practice Financing
April 27th 2017Barbara McAneny, MD, the chief executive officer of New Mexico Cancer Center, discusses how oral targeted therapies and immunotherapies disrupted the traditional methods for financing community practices.
Watch
Immune Stimulant No Help When Added to Chemotherapy for Recurrent Ovarian Cancer
March 16th 2017Adding an immunotherapeutic agent to chemotherapy had no impact on survival in patients with recurrent, platinum-resistant ovarian cancer, according to a late-breaking trial reported at the 2017 Society of Gynecologic Oncology Annual Meeting.
Read More
HPV-Targeting Therapy Tops Survival Mark in Metastatic Cervical Cancer
March 16th 2017An immunotherapy targeting human papillomavirus-infected cells led to an unprecedented 1-year survival in patients with recurrent, metastatic cervical cancer, according to a phase II study reported at the 2017 Society of Gynecology Oncology Annual Meeting.
Read More
Gene Expression Signature Predicts Outcomes in Endometrial Cancer
March 15th 2017A 7-transcript classifiers effectively predicted metastatic disease for patients with endometrioid endometrial cancer, with added promise shown when the gene expression signature was combined with pathologic features.
Read More
Big Increase in PFS With Maintenance Olaparib for BRCA+ Ovarian Cancer
March 15th 2017Patients with relapsed, platinum-sensitive <em>BRCA</em>-mutant ovarian cancer experienced a 13.6-month improvement in progression-free survival (PFS) with the PARP inhibitor olaparib versus placebo, according to data reported at the Society of Gynecologic Oncology meeting.
Read More
Carboplatin Desensitization Leads to Improved OS in Ovarian Cancer
March 15th 2017Patients with <em>BRCA</em>-proficient ovarian cancer who were treated with a carboplatin desensitization regimen had an improved overall survival (OS), according to a retrospective analysis reported at the 2017 Society of Gynecologic Oncology Annual Meeting.
Read More
Expert Discusses Success Seen With Niraparib Maintenance Therapy for Ovarian Cancer
March 15th 2017Ursula A. Matulonis, MD, discusses results of the phase III NOVA trial showed the PARP inhibitor niraparib demonstrated an improvement in PFS versus placebo as a maintenance therapy for patients with high-grade serous ovarian cancer.
Read More
Neoadjuvant Chemotherapy for Patients With High-Grade Endometrial Cancer
March 14th 2017Alon Altman, MD, associate professor, Department of Obstertrics, Gynecology and Reproductive Sciences, University of Manitoba, discusses neoadjuvant chemotherapy for patients with high-grade serous carcinoma. Across the world, many centers have shifted to more patients receiving neoadjuvant chemotherapy followed by surgery and further chemotherapy.
Watch
PARP Inhibitor Benefit in Ovarian Cancer Unaffected by BRCA Status
March 14th 2017Results of a recent phase III trial suggested that the PARP inhibitor niraparib warrants consideration for patients with recurrent, platinum-sensitive, high-grade ovarian cancer, irrespective of <em>BRCA</em> status, a reviewer of the study concluded.
Read More
Readmission Rates Misleading in Ovarian Cancer
March 14th 2017Patients with ovarian cancer who were treated at the highest volume centers had superior overall survival but also higher readmission rates compared with lower volume hospitals, casting doubt on the value of this measure for patients with cancer.
Read More
Expert Explains the Importance of Genetic Testing for Patients With Ovarian Cancer
March 14th 2017During the Society for Gynecologic Oncology 48th Annual Meeting in National Harbor, Maryland, Jubilee Brown, MD, offered advice on where to access this counseling and why it is so important for women with ovarian cancer to advocate for genetic testing.
Read More
Rucaparib Promising Agent for Patients With Relapsed Ovarian Cancer
March 14th 2017Patients with relapsed, platinum-sensitive, high-grade, ovarian cancer saw activity with the PARP inhibitor rucaparib, according to findings from the ARIEL2 study presented at the Society for Gynecologic Oncology 48th Annual Meeting in National Harbor, Maryland.
Read More
Next Steps for Treatment of Ovarian Cancer
March 14th 2017Elizabeth Swisher, MD, professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses next steps regarding treatments for patients with ovarian cancer. Combinations of PARP inhibitors with other DNA repair agents or even with immunotherapy has started to interest researchers.
Watch
Tumor Gene Methylation May Predict Ovarian Cancer Response to PARP Inhibitor
March 13th 2017Hypermethylation of 2 wild-type tumor-associated genes increased ovarian cancer responsiveness to the PARP inhibitor rucaparib, according to a subgroup analysis of the randomized ARIEL2 trial presented at the 2017 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.
Read More